autologous transplant vs chimeric antigen rec. t-cell therapy for relapsed dlbcl in partial rem.
Published 2 years ago • 313 plays • Length 45:36Download video MP4
Download video MP3
Similar videos
-
2:06
car-t therapy vs autologous transplantation in r/r dlbcl
-
1:31
car-t therapy versus autosct in dlbcl
-
0:44
autologous transplantation in dlbcl and unmet needs
-
6:13
lymphoma: overview of chimeric antigen receptor (car) t cells
-
47:52
gut microbiome correlates of response and toxicity following anti cd19 car t cell therapy
-
3:05
can car-t cells replace asct in dlbcl?
-
0:59
axi-cel as second-line therapy for r/r large b-cell lymphoma
-
0:54
next steps for car t cells in b-cell lymphomas
-
23:03
car-t cells in multiple myeloma
-
5:45
what are the options for cell-based therapies in mantle cell lymphoma?
-
34:53
engineered t cell with cars and tcrs for hematologic malignancy
-
1:06
car t-cell manufacturing: the ucl group's experience
-
3:47
can car-t cells replace asct in dlbcl?
-
1:27
qol: car t-cell therapy vs. transplant
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
1:20
reengineering chimeric antigen receptor t cells for targeted therapy of autoimmunity
-
20:15
ictc: session 3a - update on the results of car t cells in all
-
1:39
the role of myeloid cells in car-t cell therapy
-
2:55
cd19 car t-cell therapy for lymphoma